Connection
David Badesch to Endothelin A Receptor Antagonists
This is a "connection" page, showing publications David Badesch has written about Endothelin A Receptor Antagonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.164 |
|
|
|
-
Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9.
Score: 0.096
-
Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006 May 16; 47(10):2049-56.
Score: 0.067